Neurocrine Biosciences Inc
$
85.76
-0.26 (-0.3%)
| Volume: | 453,088 | Avg Vol (1m): | 852,247 |
| Market Cap $: | 7.85 Bil | Enterprise Value $: | 7.72 Bil |
| P/E (TTM): | 0.00 | P/B: | 19.14 |
| Earnings Power Value | -6.44 |
| Net Current Asset Value | 0.93 |
| Tangible Book | 4.5 |
| Projected FCF | -2.89 |
| Median P/S Value | 209.34 |
| Graham Number | 4.5 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.33 |
Cash-To-Debt ranked
lower than
77.09%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NBIX:
1.33
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 1.23, Med: 37.47, Max: 10000
Current: 1.33
|
| Equity-to-Asset | 0.43 |
Equity-to-Asset ranked
lower than
74.71%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NBIX:
0.43
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.01, Med: 0.78, Max: 0.95
Current: 0.43
|
| Debt-to-Equity | 0.96 |
Debt-to-Equity ranked
lower than
83.40%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
NBIX:
0.96
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.13, Max: 16.07
Current: 0.96
|
| Debt-to-EBITDA | -120.98 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
NBIX:
-120.98
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -120.98, Med: 1.91, Max: 6.89
Current: -120.98
|
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 7.74 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -1.95 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -10.8%
WACC 10.21%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -5.14 |
Operating Margin ranked
higher than
66.16%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NBIX:
-5.14
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -1730.88, Med: -81.27, Max: 43.82
Current: -5.14
|
| Net Margin % | -7.56 |
Net Margin ranked
higher than
65.53%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NBIX:
-7.56
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -1728.34, Med: -88.19, Max: 48.53
Current: -7.56
|
| ROE % | -9.42 |
ROE ranked
higher than
68.86%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NBIX:
-9.42
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -250.63, Med: -35.17, Max: 94.61
Current: -9.42
|
| ROA % | -4.32 |
ROA ranked
higher than
73.62%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NBIX:
-4.32
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -54.01, Med: -24.44, Max: 26.57
Current: -4.32
|
| ROC (Joel Greenblatt) % | -22.39 |
ROC (Joel Greenblatt) ranked
higher than
62.36%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NBIX:
-22.39
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -3011.27, Med: -1295.38, Max: 2175.88
Current: -22.39
|
| 3-Year Total Revenue Growth Rate | 183.70 |
3-Year Revenue Growth Rate ranked
lower than
100.00%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NBIX:
172.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -10.75, Max: 172.4
Current: 172.4
|
» NBIX's 30-Y Financials
Financials (Next Earnings Date: 2019-07-31)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:NBIX
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325414   SIC : 2836 |
| Compare | SZSE:000661 NAS:ALNY NAS:MRNA NAS:TECH HKSE:06160 NAS:JAZZ NAS:BLUE XAMS:GLPG NAS:EXEL NAS:ASND NAS:ARRY TSE:4587 NAS:NKTR NAS:AMRN SZSE:002007 NAS:SRPT NAS:SAGE NAS:IONS SZSE:002252 XBRU:ARGX |
| Traded in other countries | NB3.Germany 0K6R.UK |
| Address | 12780 El Camino Real, San Diego, CA, USA, 92130 |
| Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 19.14 |
PB Ratio ranked
lower than
95.11%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NBIX:
19.14
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.35, Med: 10.1, Max: 120
Current: 19.14
|
| PS Ratio | 15.55 |
PS Ratio ranked
lower than
68.87%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NBIX:
15.55
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 3.86, Med: 37.8, Max: 3581.82
Current: 15.55
|
| Price-to-Operating-Cash-Flow | 372.36 |
Price-to-Operating-Cash-Flow ranked
lower than
97.62%
of
210
companies
in the
Biotechnology
industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
NBIX:
372.36
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.82, Med: 67.59, Max: 819.67
Current: 372.36
|
| EV-to-EBIT | -958.50 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NBIX:
-958.5
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -1015.4, Med: -19.8, Max: 426.3
Current: -958.5
|
| EV-to-EBITDA | -2374.48 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NBIX:
-2374.48
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -2515.4, Med: -20.3, Max: 293.3
Current: -2374.48
|
| EV-to-Revenue | 14.90 |
EV-to-Revenue ranked
lower than
64.85%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NBIX:
14.9
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: -3, Med: 27.1, Max: 3853
Current: 14.9
|
| Current Ratio | 8.79 |
Current Ratio ranked
higher than
73.93%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NBIX:
8.79
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.57, Med: 9.63, Max: 26.66
Current: 8.79
|
| Quick Ratio | 8.61 |
Quick Ratio ranked
higher than
74.77%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NBIX:
8.61
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.55, Med: 9.63, Max: 26.66
Current: 8.61
|
| Days Inventory | 431.09 |
Days Inventory ranked
higher than
90.85%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NBIX:
431.09
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 149.03, Med: 296.4, Max: 443.76
Current: 431.09
|
| Days Sales Outstanding | 50.65 |
Days Sales Outstanding ranked
higher than
65.42%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NBIX:
50.65
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 45.49, Med: 57.89, Max: 70.29
Current: 50.65
|
| Days Payable | 993.96 |
Days Payable ranked
lower than
86.94%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NBIX:
993.96
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 993.96, Med: 1337.16, Max: 1643.96
Current: 993.96
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -1.70 |
3-Year Share Buyback Rate ranked
higher than
75.61%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NBIX:
-1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -17, Med: -8, Max: -1.3
Current: -1.7
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 19.12 |
Price-to-Tangible-Book ranked
lower than
92.51%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NBIX:
19.12
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 1.11, Med: 5.19, Max: 112.96
Current: 19.12
|
| Price-to-Median-PS-Value | 0.41 |
Price-to-Median-PS-Value ranked
higher than
61.65%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NBIX:
0.41
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.1, Med: 0.7, Max: 37.31
Current: 0.41
|
| Price-to-Graham-Number | 19.18 |
Price-to-Graham-Number ranked
lower than
100.00%
of
200
companies
in the
Biotechnology
industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
NBIX:
19.18
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 1.17, Med: 1.51, Max: 52.1
Current: 19.18
|
| Earnings Yield (Joel Greenblatt) % | -0.11 |
Earnings Yield (Greenblatt) ranked
higher than
75.12%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NBIX:
-0.11
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -808.8, Med: -3.1, Max: 1635.4
Current: -0.11
|
More Statistics
| Revenue (TTM) (Mil) $ | 518.56 |
| EPS (TTM) $ | -0.48 |
| Beta | 1.37 |
| Volatility % | 56.06 |
| 52-Week Range $ | 64.72 - 126.98 |
| Shares Outstanding (Mil) | 90.8 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | N |